Because there are no companies around which can produce mRNA vaccine. The production process is very specific. Opening up the patents wouldn't help. There are c

Because there are no companies around which can produce mRNA vaccine. The production process is very specific. Opening up the patents wouldn't help. There are cooperations with those production steps which are generic, like botteling of the vaccines. Fortunately, another factory for BioNTech (which are the people who are making the vaccine, Pfizer is just the large partner) opened up in Germany recently and is going to produce a significant amount of doses. But instead of 1 more like 10 of these factories should have been built.